Chronic pulmonary aspergillosis (Q38424): Difference between revisions

From determinar.ia.br - Determine suas informações
Changed an Item
Changed an Item
 
Property / Linked ICD 10
 
Property / Linked ICD 10: B44.1 / rank
 
Normal rank

Latest revision as of 03:27, 13 August 2026

Chronic pulmonary aspergillosis (CPA) presents as nodular or cavitary lesion(s) in the lungs, of at least three months duration. It is caused by Aspergillus species as demonstrated on histological staining, by positive culture of biopsy, or positive Aspergillus IgG antibodies. The most common form of CPA is chronic cavitary pulmonary aspergillosis (CCPA). Untreated it may progress to chronic fibrosing pulmonary aspergillosis (CFPA). Less common manifestations of CPA include Aspergillus nodule and single aspergilloma. All these entities are found in non-immunocompromised patients with prior or current lung disease. Subacute invasive pulmonary aspergillosis (formerly called chronic necrotising pulmonary aspergillosis) is a more rapidly progressive infection (<3 months) usually found in moderately immunocompromised patients.
Language Label Description Also known as
default for all languages
1F20.12
    English
    Chronic pulmonary aspergillosis
    Chronic pulmonary aspergillosis (CPA) presents as nodular or cavitary lesion(s) in the lungs, of at least three months duration. It is caused by Aspergillus species as demonstrated on histological staining, by positive culture of biopsy, or positive Aspergillus IgG antibodies. The most common form of CPA is chronic cavitary pulmonary aspergillosis (CCPA). Untreated it may progress to chronic fibrosing pulmonary aspergillosis (CFPA). Less common manifestations of CPA include Aspergillus nodule and single aspergilloma. All these entities are found in non-immunocompromised patients with prior or current lung disease. Subacute invasive pulmonary aspergillosis (formerly called chronic necrotising pulmonary aspergillosis) is a more rapidly progressive infection (<3 months) usually found in moderately immunocompromised patients.

      Statements

      CID11:1F20.12
      0 references
      dki-india-1F20.12
      0 references
      Concluído
      0 references
      13 August 2026
      0 references
      0 references